FGEN Company Profile and Key Details

Q: Who are the executives of FGEN?

Ms. Christine L. ChungSenior Vice President of China OperationsMr. Enrique A. ConternoChief Executive Officer & DirectorDr. Elias KouchakjiSenior Vice President of Clinical Devel., Drug Safety & PharmacovigilanceDr. Barry A. Berkowitz Ph.D.FounderDr. John J. Hunter Ph.D.Chief Scientific OfficerDr. Mark Eisner M.D., M.P.H.Executive Vice President & Chief Medical OfficerMr. Michael D. Lowenstein J.D., Ph.D.Chief Legal OfficerMr. Thane WettigInterim Chief Executive Officer, Executive Vice President & Chief Commercial OfficerMr. Juan GrahamSenior Vice President & Chief Financial OfficerMs. Tricia StewartChief People Officer

NASDAQ : FGEN

FibroGen

$9.07

-0.15-1.63%

At Close 4:00 PM

Not Actively Trading

55.69

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

FibroGen, Inc. (FGEN) stock declined over -1.63%, trading at $9.07 on NASDAQ, down from the previous close of $9.22. The stock opened at $9.10, fluctuating between $9.02 and $9.21 in the recent session.

Stock Snapshot

9.22

Prev. Close

36.69M

Market Cap

9.02

Day Low

-0.7058365758754864

P/E Ratio

-12.85

EPS (TTM)

-3.22

Cash Flow per Share

9.1

Open

4.05M

Number of Shares

9.21

Day High

89.72%

Free Float in %

-2.07

Book Value

29.26K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jan 07, 2026	9.23	9.75	9.23	9.71	31.13K
Jan 06, 2026	9.01	9.33	8.86	9.02	22.75K
Jan 05, 2026	8.90	9.32	8.83	8.93	16.83K
Jan 02, 2026	8.75	9.32	8.73	9.16	27.93K
Dec 31, 2025	8.74	8.98	8.50	8.78	33.17K
Dec 30, 2025	8.66	8.98	8.62	8.70	25.04K
Dec 29, 2025	8.76	9.19	8.60	8.78	28.65K
Dec 26, 2025	8.51	9.00	8.36	8.90	28.66K
Dec 24, 2025	8.42	8.59	8.38	8.59	7.21K
Dec 23, 2025	8.52	8.79	8.42	8.43	26.05K
Dec 22, 2025	8.50	8.80	8.50	8.56	23.53K
Dec 19, 2025	8.35	8.92	8.35	8.60	32.5K
Dec 17, 2025	9.48	9.51	8.66	8.66	50.85K
Dec 16, 2025	9.82	10.47	9.30	9.51	47.77K
Dec 15, 2025	8.66	10.45	8.60	10.04	335.43K
Dec 12, 2025	8.71	8.80	8.37	8.38	11.66K
Dec 11, 2025	8.77	9.09	8.70	8.70	12.2K
Dec 10, 2025	8.42	8.98	8.42	8.82	15.67K
Dec 09, 2025	8.42	8.64	8.38	8.51	18.34K
Dec 08, 2025	8.51	8.54	8.34	8.36	14.56K

Contact Details

San Francisco, CA 94158

United States

https://www.fibrogen.com 415 978 1200

About Company

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Stock Peers

ARGX

5.7+0.73%

argenx SE$781.72 REGN

20.7+3.02%

Regeneron Pharmaceuticals, Inc.$707.06 UTHR

0.28+0.05%

United Therapeutics Corporation$571.35 MDGL

-1.19-0.23%

Madrigal Pharmaceuticals, Inc.$517.39 VRTX

4.14+0.98%

Vertex Pharmaceuticals Incorporated$427.38 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-4.36-1.35%

Praxis Precision Medicines, Inc.$318.83 ALNY

8.3+2.76%

Alnylam Pharmaceuticals, Inc.$309.49 KRYS

2.31+0.89%

Krystal Biotech, Inc.$262.26 LGND

4.59+2.04%

Ligand Pharmaceuticals Incorporated$229.45

Frequently Asked Questions

What is the current FibroGen, Inc. (FGEN) stock price?

FibroGen, Inc. (NASDAQ: FGEN) stock price is $9.07 in the last trading session. During the trading session, FGEN stock reached the peak price of $9.21 while $9.02 was the lowest point it dropped to. The percentage change in FGEN stock occurred in the recent session was -1.63% while the dollar amount for the price change in FGEN stock was - $0.15.

FGEN's industry and sector of operation?

The NASDAQ listed FGEN is part of Biotechnology industry that operates in the broader Healthcare sector. FibroGen, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of FGEN?

Ms. Christine L. Chung
Senior Vice President of China Operations
Mr. Enrique A. Conterno
Chief Executive Officer & Director
Dr. Elias Kouchakji
Senior Vice President of Clinical Devel., Drug Safety & Pharmacovigilance
Dr. Barry A. Berkowitz Ph.D.
Founder
Dr. John J. Hunter Ph.D.
Chief Scientific Officer
Dr. Mark Eisner M.D., M.P.H.
Executive Vice President & Chief Medical Officer
Mr. Michael D. Lowenstein J.D., Ph.D.
Chief Legal Officer
Mr. Thane Wettig
Interim Chief Executive Officer, Executive Vice President & Chief Commercial Officer
Mr. Juan Graham
Senior Vice President & Chief Financial Officer
Ms. Tricia Stewart
Chief People Officer

How FGEN did perform over past 52-week?

FGEN's closing price is 87.01% higher than its 52-week low of $4.85 where as its distance from 52-week high of $21.95 is -58.68%.

How many employees does FGEN have?

Number of FGEN employees currently stands at 225.

Link for FGEN official website?

Official Website of FGEN is: https://www.fibrogen.com

How do I contact FGEN?

FGEN could be contacted at phone 415 978 1200 and can also be accessed through its website. FGEN operates from 409 Illinois Street, San Francisco, CA 94158, United States.

How many shares of FGEN are traded daily?

FGEN stock volume for the day was 29.26K shares. The average number of FGEN shares traded daily for last 3 months was 33.23K.

What is the market cap of FGEN currently?

The market value of FGEN currently stands at $36.69M with its latest stock price at $9.07 and 4.05M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	225
Beta	0.77
Sales or Revenue	$147.75M
5Y Sales Change%	-0.81%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	225
Beta	0.77
Sales or Revenue	$147.75M
5Y Sales Change%	-0.81%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

FGEN Company Profile and Key Details

FibroGen

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Company Overview

Shareholding & Insider Activity

Dividend & Fair Value

Valuation Metrics

Price Forecast & Outlook

Key Takeaways